Clinical electrophysiological features and efficacy of anti-epileptic drugs of patients with Juvenile myoclonic epilepsy_Journal of Epilepsy

Authors：

 GAOYu ¹ ^* ,  WEIXiaoshan ² ^* ,  WANGYuping ¹

1. Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China;
2. Department of Neurology, Traditional Chinese Medicin Hospital of Shijiazhuang, Shijiazhuang 050001, China;

Corresponding author：

WANGYuping, Email: wangyuping01@sina.cn

Keywords：

Juvenile myoclonic epilepsy; Clinical manifestation; Electrophysiological feature; Efficacy of AEDs

DOI：

10.7507/2096-0247.20160002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize clinical electrophysiological features and efficacy of some of Anti-epileptic drugs(AEDs) of Juvenile myoclonic epilepsy (JME). Methods Clinical electrophysiological information of 101 outpatients with JME observed at Xuanwu Hospital from Jul. 2001 to Sep. 2014 was retrospectively analyzed, including the seizure types, trigger factors, electroencephalogram. We followed some of these patients and compared the efficacy between different AEDs. Result According to different seizure types, there are four subtypes: Myoclonus (MJ) only 11.88%, MJ+generalized tonic-clonic seizure(GTCS) 75.24%, MJ+GTCS+Absence(Abs) 11.88%, MJ+Abs 1.00%. Patients with typical ictal generalized poly-spike and waves (PSW) or spike and waves (SW) or spikes account for 96.80%. And 75.00% of patients have no MJ and 91.80% have no GTCS with valproic acid monotherapy. 65.00% and 88.24% of patients were seizure free of MJ and GTCS recpectively. But the difference of efficacy between these two drugs have no statistically significance. Sleep deprivation was the primary trigger factors, accounting for 16.83%. Conclusion JME has clinical heterogeinety, clinicians should fully understand the whole condition of JME individual, including their clinical manifestation, EEG features, reaction to AEDs, trigger factors, habitual patterns and so on, in order to help making individualized therapy.

Citation： GAOYu, WEIXiaoshan, WANGYuping. Clinical electrophysiological features and efficacy of anti-epileptic drugs of patients with Juvenile myoclonic epilepsy. Journal of Epilepsy, 2016, 2(1): 9-13. doi: 10.7507/2096-0247.20160002 Copy

1.	Genton P, Thomas P, Kasteleijn-Nolst Trenité DGA, et al. Clinical aspects of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 8-14.
2.	Hofler J, Unterberger I, Dobesberger J, et al. Seizure outcome in 175 patients with juvenile myoclonic epilepsy--a long-term observational study. Epilepsy Res, 2014, 108(10): 1817-1824.
3.	Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia, 1989, 30(4): 389-399.
4.	KasteleijnNolst Trenité DGA, Schmitz B, Janz D, et al. Consensus on diagnosis and management of JME: From founder's observations to current trends. Epilepsy & Behavior, 2013, 28(Suppl 1): 87-90.
5.	Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 15-17.
6.	MartinezJuarez IE, Alonso ME, Medina MT, et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain, 2006, 129(5): 1269-1280.
7.	Baykan B, MartínezJuárez IE, Altindag EA, et al. Lifetime prognosis of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 18-24.
8.	Senf P, Schmitz B, Holtkamp M, et al. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Neurology, 2013, 81(24): 2128-2133.
9.	Panayiotopoulos CP, Obeid T, Waheed G. Absences in juvenile myoclonic epilepsy: a clinical and video-electroencephalographic study. Ann Neurol, 1989, 25(4): 391-397.
10.	Serafini A, Rubboli G, Gigli GL, et al. Neurophysiology of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 30-39.
11.	FernandoDongas MC, Radtke RA, Vanlandingham KE, et al. Characteristics of valproic acid resistant juvenile myoclonic epilepsy. Seizure, 2000, 9(6): 385-388.
12.	Crespel A, Gelisse P, Reed RC, et al. Management of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 81-86.
13.	Machado RA, Garcia VF, Astencio AG, et al. Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial. Seizure, 2013, 22(10): 846-855.
14.	Bodenstein-Sachar H, GandelmanMarton R, BenZeev B, et al. Outcome of lamotrigine treatment in juvenile myoclonic epilepsy. Acta Neurol Scand, 2011, 124(1): 22-27.
15.	KasteleijnNolst Trenité DGA, de Weerd A, Beniczky S. Chronodependency and provocative factors in juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28( Suppl 1): 25-29.
16.	Krishnan P, Sinha S, Taly AB, et al. Sleep disturbances in juvenile myoclonic epilepsy: a sleep questionnaire-based study. Epilepsy Behav, 2012, 23(3): 305-309.
17.	AsadiPooya AA, Hashemzehi Z, Emami M. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME). Seizure, 2014, 23(10): 889-891.

1. Genton P, Thomas P, Kasteleijn-Nolst Trenité DGA, et al. Clinical aspects of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 8-14.
2. Hofler J, Unterberger I, Dobesberger J, et al. Seizure outcome in 175 patients with juvenile myoclonic epilepsy--a long-term observational study. Epilepsy Res, 2014, 108(10): 1817-1824.
3. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia, 1989, 30(4): 389-399.
4. KasteleijnNolst Trenité DGA, Schmitz B, Janz D, et al. Consensus on diagnosis and management of JME: From founder's observations to current trends. Epilepsy & Behavior, 2013, 28(Suppl 1): 87-90.
5. Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 15-17.
6. MartinezJuarez IE, Alonso ME, Medina MT, et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain, 2006, 129(5): 1269-1280.
7. Baykan B, MartínezJuárez IE, Altindag EA, et al. Lifetime prognosis of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 18-24.
8. Senf P, Schmitz B, Holtkamp M, et al. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Neurology, 2013, 81(24): 2128-2133.
9. Panayiotopoulos CP, Obeid T, Waheed G. Absences in juvenile myoclonic epilepsy: a clinical and video-electroencephalographic study. Ann Neurol, 1989, 25(4): 391-397.
10. Serafini A, Rubboli G, Gigli GL, et al. Neurophysiology of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 30-39.
11. FernandoDongas MC, Radtke RA, Vanlandingham KE, et al. Characteristics of valproic acid resistant juvenile myoclonic epilepsy. Seizure, 2000, 9(6): 385-388.
12. Crespel A, Gelisse P, Reed RC, et al. Management of juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28(Suppl 1): 81-86.
13. Machado RA, Garcia VF, Astencio AG, et al. Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial. Seizure, 2013, 22(10): 846-855.
14. Bodenstein-Sachar H, GandelmanMarton R, BenZeev B, et al. Outcome of lamotrigine treatment in juvenile myoclonic epilepsy. Acta Neurol Scand, 2011, 124(1): 22-27.
15. KasteleijnNolst Trenité DGA, de Weerd A, Beniczky S. Chronodependency and provocative factors in juvenile myoclonic epilepsy. Epilepsy & Behavior, 2013, 28( Suppl 1): 25-29.
16. Krishnan P, Sinha S, Taly AB, et al. Sleep disturbances in juvenile myoclonic epilepsy: a sleep questionnaire-based study. Epilepsy Behav, 2012, 23(3): 305-309.
17. AsadiPooya AA, Hashemzehi Z, Emami M. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME). Seizure, 2014, 23(10): 889-891.

Previous Article
非惊厥性癫痫持续状态一例

Journal of Epilepsy

Clinical electrophysiological features and efficacy of anti-epileptic drugs of patients with Juvenile myoclonic epilepsy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content